Meeting
2013 ASCO Annual Meeting
A phase I clinical trial of veliparib and temozolomide in children with recurrent central nervous system tumors: A Pediatric Brain Tumor Consortium report.
Authors
Jack M. Su
Texas Children's Cancer Center, Baylor College of Medicine, Houston, TX
Jack M. Su , Patrick Andrew Thompson , Adekunle Adesina , Xiao-Nan Li , Lindsay Baker Kilburn , Arzu Onar-Thomas , Mehmet Kocak , Brenda Chyla , Evelyn Mary McKeegan , Katherine E. Warren , Stewart Goldman , Ian Pollack , Maryam Fouladi , Alice Chen , Malcolm A. Smith , Vincent L. Giranda , James M. Boyett , Susan Blaney , Larry E. Kun
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT00946335
Citation
J Clin Oncol 31, 2013 (suppl; abstr 2036)
DOI
10.1200/jco.2013.31.15_suppl.2036
Abstract #
2036
Poster Bd #
25
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Phase I adult brain tumor consortium (ABTC) trial of ABT-888 (veliparib), temozolomide (TMZ), and radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM) including pharmacokinetic (PK) data.
First Author: Lawrence Kleinberg
Poster
2018 ASCO Annual Meeting
Phase I clinical trials evaluating olaparib in combination with radiotherapy (RT) and/or temozolomide (TMZ) in glioblastoma patients: Results of OPARATIC and PARADIGM phase I and early results of PARADIGM-2.
First Author: Anthony J. Chalmers
First Author: Stuart Cramer
Poster
2021 ASCO Annual Meeting
Phase 1 study of pevonedistat (MLN4924) a NEDD8 activating enzyme inhibitor, in combination with temozolomide (TMZ) and irinotecan (IRN) in pediatric patients with recurrent or refractory solid tumors (ADVL1615).
First Author: Jennifer Foster